Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 96

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors

Aslanoglou, Despoina, Bertera, Suzanne, Sánchez-Soto, Marta, Benjamin Free, R., Lee, Jeongkyung, Zong, Wei, Xue, Xiangning, Shrestha, Shristi, Brissova, Marcela, Logan, Ryan W., Wollheim, Claes B., Trucco, Massimo, Yechoor, Vijay K., Sibley, David R., Bottino, Rita, Freyberg, Zachary · 2021 · Translational Psychiatry

Abstract

Dopamine (DA) and norepinephrine (NE) are catecholamines primarily studied in the central nervous system that also act in the pancreas as peripheral regulators of metabolism. Pancreatic catecholamine signaling has also been increasingly implicated as a mechanism responsible for the metabolic disturbances produced by antipsychotic drugs (APDs). Critically, however, the mechanisms by which catecholamines modulate pancreatic hormone release are not completely understood. We show that human and mouse pancreatic α- and β-cells express the catecholamine biosynthetic and signaling machinery, and that α-cells synthesize DA de novo. This locally-produced pancreatic DA signals via both α- and β-cell adrenergic and dopaminergic receptors with different affinities to regulate glucagon and insulin release. Significantly, we show DA functions as a biased agonist at α 2A-adrenergic receptors, preferentially signaling via the canonical G protein-mediated pathway. Our findings highlight the interplay between DA and NE signaling as a novel form of regulation to modulate pancreatic hormone release. Lastly, pharmacological blockade of DA D 2-like receptors in human islets with APDs significantly raises insulin and glucagon release. This offers a new mechanism where APDs act directly on islet α- and β-cell targets to produce metabolic disturbances.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-020-01171-z

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 89

  1. Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M. & Stafford, R. S. Increasing off-label use of antipsychotic medications in the United States, 1995−2008. Pharmacoepidemiol. Drug Saf. 20, 177–184 (2011). · DOI · Paper page
  2. Ballon, J. S., Pajvani, U., Freyberg, Z., Leibel, R. L. & Lieberman, J. A. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol. Metab. 25, 593–600 (2014). · DOI
  3. Freyberg, Z., Aslanoglou, D., Shah, R. & Ballon, J. S. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front. Neurosci. 11, 432 (2017). · DOI
  4. Rubi, B. et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 280, 36824–36832 (2005). · DOI · Paper page
  5. Simpson, N. et al. Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro. Mol. Endocrinol. 26, 1757–1772 (2012). · DOI · Paper page
  6. Farino, Z. J. et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol. Psychiatry 25, 2070–2085 (2020). · DOI
  7. Farino, Z. J. et al. Development of a rapid insulin assay by homogenous time-resolved fluorescence. PLoS ONE 11, e0148684 (2016). · DOI
  8. Ustione, A. & Piston, D. W. Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations. Mol. Endocrinol. 26, 1928–1940 (2012). · DOI · Paper page
  9. Merglen, A. et al. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145, 667–678 (2004). 2004. · DOI · Paper page
  10. Garcia-Tornadu, I. et al. Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 151, 1441–1450 (2010). · DOI
  11. Rosati, G., Maioli, M., Aiello, I., Farris, A. & Agnetti, V. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. Eur. Neurol. 14, 229–239 (1976). · doi:10.1159/000114744
  12. Ericson, L. E., Hakanson, R. & Lundquist, I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 13, 117–124 (1977). · DOI
  13. Zern, R. T., Bird, J. L. & Feldman, J. M. Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster. Diabetologia 18, 341–346 (1980). · DOI
  14. Elias, A. N. & Hofflich, H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am. J. Med. 121, 98–104 (2008). · DOI
  15. Charron, M. J. & Vuguin, P. M. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J. Endocrinol. 224, R123–R130 (2015). · DOI
  16. Knop, F. K. EJE PRIZE 2018: a gut feeling about glucagon. Eur. J. Endocrinol. 178, R267–R280 (2018). · DOI · Paper page
  17. Smith, G. C., Chaussade, C., Vickers, M., Jensen, J. & Shepherd, P. R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51, 2309–2317 (2008). · DOI
  18. Nagata, M., Kimura, Y., Ishiwata, Y., Takahashi, H. & Yasuhara, M. Clozapine-induced acute hyperglycemia is accompanied with elevated serum concentrations of adrenaline and glucagon in rats. Biol. Pharm. Bull. 41, 1286–1290 (2018). · DOI
  19. Castellani, L. N. et al. Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia. Psychoneuroendocrinology 82, 38–45 (2017). · DOI
  20. Chen, Y. et al. Distinctive expression and cellular distribution of dopamine receptors in the pancreatic islets of rats. Cell Tissue Res. 357, 597–606 (2014). · DOI
  21. Zhang, Y. et al. Pancreatic endocrine effects of dopamine receptors in human islet cells. Pancreas 44, 925–929 (2015). · DOI
  22. Sorenson, R. L., Elde, R. P. & Seybold, V. Effect of norepinephrine on insulin, glucagon, and somatostatin secretion in isolated perifused rat islets. Diabetes 28, 899–904 (1979). · DOI
  23. Thorens, B. Neural regulation of pancreatic islet cell mass and function. Diabetes Obes. Metab. 16, 87–95 (2014). · DOI · Paper page
  24. Rodriguez-Diaz, R. & Caicedo, A. Neural control of the endocrine pancreas. Best. Pr. Res Clin. Endocrinol. Metab. 28, 745–756 (2014). · DOI
  25. Lorenzi, M. et al. Dopamine during alpha- or beta-adrenergic blockade in man. Hormonal, metabolic, and cardiovascular effects. J. Clin. Invest. 63, 310–317 (1979). · DOI
  26. Lorenzi, M. et al. Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon. J. Clin. Endocrinol. Metab. 45, 1154–1158 (1977). · DOI
  27. Chaudhry, S., Bernardes, M., Harris, P. E. & Maffei, A. Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Miner. Endocrinol. 41, 43–56 (2016).
  28. Tang, S. C. et al. Human pancreatic neuro-insular network in health and fatty infiltration. Diabetologia 61, 168–181 (2018). · DOI
  29. Gylfe, E. & Tengholm, A. Neurotransmitter control of islet hormone pulsatility. Diabetes Obes. Metab. 16, 102–110 (2014). · DOI
  30. Ustione, A., Piston, D. W. & Harris, P. E. Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet. Mol. Endocrinol. 27, 1198–1207 (2013). · DOI
  31. Maffei, A., Segal, A. M., Alvarez-Perez, J. C., Garcia-Ocaña, A. & Harris, P. E. Anti-incretin, anti-proliferative action of dopamine on β-cells. Mol. Endocrinol. 29, 542–557 (2015). · DOI
  32. Iturriza, F. C. & Thibault, J. Immunohistochemical investigation of tyrosine-hydroxylase in the islets of Langerhans of adult mice, rats and guinea pigs. Neuroendocrinology 57, 476–480 (1993). · doi:10.1159/000126394
  33. Persson-Sjogren, S., Forsgren, S. & Taljedal, I. B. Tyrosine hydroxylase in mouse pancreatic islet cells, in situ and after syngeneic transplantation to kidney. Histol. Histopathol. 17, 113–121 (2002).
  34. Takayanagi, M. & Watanabe, T. Immunocytochemical colocalizations of insulin, aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, S-100 protein and chromogranin A in B-cells of the chicken endocrine pancreas. Tissue Cell 28, 17–24 (1996). · DOI
  35. Newcomer, J. W. et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psych. 59, 337–345 (2002). · DOI · Paper page
  36. Aslanoglou, D., George, E. W. & Freyberg, Z. Homogeneous time-resolved Forster resonance energy transfer-based assay for detection of insulin secretion. J. Vis. Exp. 135, 57531 (2018). · DOI
  37. Bertera, S., Balamurugan, A. N., Bottino, R., He, J. & Trucco, M. Increased yield and improved transplantation outcome of mouse islets with bovine serum albumin. J. Transpl. 2012, 856386 (2012).
  38. Balamurugan, A. N., Chang, Y., Fung, J. J., Trucco, M. & Bottino, R. Flexible management of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata. Am. J. Transpl. 3, 1135–1142 (2003). · DOI
  39. Hughes, J. W., Ustione, A., Lavagnino, Z. & Piston, D. W. Regulation of islet glucagon secretion: Beyond calcium. Diabetes Obes. Metab. 20, 127–136 (2018). · DOI
  40. Sánchez-Soto, M. et al. α2A- and α2C-adrenoceptors as potential targets for dopamine and dopamine receptor ligands. Mol. Neurobiol. 55, 8438–8454 (2018). · DOI
  41. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharm. 22, 3099–3108 (1973). · DOI · Paper page
  42. Brissova, M. et al. α cell function and gene expression are compromised in type 1 diabetes. Cell Rep. 22, 2667–2676 (2018). · DOI · Paper page
  43. Saunders, D. C. et al. Ectonucleoside triphosphate diphosphohydrolase-3 antibody targets adult human pancreatic beta cells for in vitro and in vivo analysis. Cell Metab. 29, 745–754.e744 (2019). · DOI
  44. Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
  45. Rouille, Y., Westermark, G., Martin, S. K. & Steiner, D. F. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc. Natl Acad. Sci. USA 91, 3242–3246 (1994). · DOI · Paper page
  46. Iversen, J. Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J. Clin. Invest. 52, 2102–2116 (1973). · DOI · Paper page
  47. Beaulieu, J. M., Espinoza, S. & Gainetdinov, R. R. Dopamine receptors - IUPHAR Review 13. Br. J. Pharm. 172, 1–23 (2015). · DOI · Paper page
  48. Hahn, M. et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr. Res. 131, 90–95 (2011). · DOI
  49. Garcia-Tornadu, I. et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse. Neuroendocrinology 92, 207–214 (2010). · DOI
  50. Korner, J. et al. A role for foregut tyrosine metabolism in glucose tolerance. Mol. Metab. 23, 37–50 (2019). · DOI
  51. Caicedo, A. Paracrine and autocrine interactions in the human islet: more than meets the eye. Semin. Cell Dev. Biol. 24, 11–21 (2013). · DOI · Paper page
  52. Begg, D. P. & Woods, S. C. Interactions between the central nervous system and pancreatic islet secretions: a historical perspective. Adv. Physiol. Educ. 37, 53–60 (2013). · DOI
  53. Cabrera, O. et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl Acad. Sci. USA 103, 2334–2339 (2006). · DOI · Paper page
  54. Mitok, K. A. et al. Islet proteomics reveals genetic variation in dopamine production resulting in altered insulin secretion. J. Biol. Chem. 293, 5860–5877 (2018). · DOI
  55. Uchino, H. et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharm. 61, 729–737 (2002). · doi:10.1124/mol.61.4.729 · Paper page
  56. Khunweeraphong, N. et al. Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with alpha-alkyl moieties. J. Pharm. Sci. 119, 368–380 (2012). · DOI
  57. Camargo, S. M. et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson’s disease. J. Pharm. Exp. Ther. 351, 114–123 (2014). · DOI
  58. Goldstein, D. S. et al. Sources and physiological significance of plasma dopamine sulfate. J. Clin. Endocrinol. Metab. 84, 2523–2531 (1999). · DOI · Paper page
  59. Eldrup, E., Moller, S. E., Andreasen, J. & Christensen, N. J. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid. Clin. Sci. 92, 423–430 (1997). · DOI
  60. Eldrup, E. & Richter, E. A. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting. Am. J. Physiol. Endocrinol. Metab. 279, E815–E822 (2000). · DOI
  61. Eldrup, E., Richter, E. A. & Christensen, N. J. DOPA, norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle DOPA. Am. J. Physiol. 256, E284–E287 (1989).
  62. Goldstein, D. S., Eisenhofer, G. & Kopin, I. J. Sources and significance of plasma levels of catechols and their metabolites in humans. J. Pharm. Exp. Ther. 305, 800–811 (2003). 2003. · DOI · Paper page
  63. Gylfe, E. & Gilon, P. Glucose regulation of glucagon secretion. Diabetes Res. Clin. Pr. 103, 1–10 (2014). · DOI
  64. Unger, R. H. & Orci, L. Paracrinology of islets and the paracrinopathy of diabetes. Proc. Natl Acad. Sci. USA 107, 16009–16012 (2010). · DOI · Paper page
  65. Lindvall, O. & Bjorklund, A. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol. Scand. Suppl. 412, 1–48 (1974).
  66. Swanson, L. W. & Hartman, B. K. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J. Comp. Neurol. 163, 467–505 (1975). · DOI · Paper page
  67. Goldman-Rakic, P. S., Lidow, M. S., Smiley, J. F. & Williams, M. S. The anatomy of dopamine in monkey and human prefrontal cortex. J. Neural Transm. Suppl. 36, 163–177 (1992).
  68. Zhang, W., Klimek, V., Farley, J. T., Zhu, M. Y. & Ordway, G. A. alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J. Pharm. Exp. Ther. 289, 1286–1292 (1999).
  69. Alachkar, A., Brotchie, J. M. & Jones, O. T. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci. Res 67, 245–249 (2010). · doi:10.1016/j.neures.2010.03.008
  70. Cornil, C. A. & Ball, G. F. Interplay among catecholamine systems: dopamine binds to alpha2-adrenergic receptors in birds and mammals. J. Comp. Neurol. 511, 610–627 (2008). · DOI
  71. Cornil, C. A., Castelino, C. B. & Ball, G. F. Dopamine binds to alpha(2)-adrenergic receptors in the song control system of zebra finches (Taeniopygia guttata). J. Chem. Neuroanat. 35, 202–215 (2008). · DOI
  72. Parrado, A. C. et al. Differential response of dopamine mediated by beta-adrenergic receptors in human keratinocytes and macrophages: potential implication in wound healing. Neuroimmunomodulation 24, 282–291 (2017). · DOI
  73. Habuchi, Y. et al. Dopamine stimulation of cardiac beta-adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. Br. J. Pharm. 122, 1669–1678 (1997). · doi:10.1038/sj.bjp.0701574
  74. Weichert, D., Stanek, M., Hubner, H. & Gmeiner, P. Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists. Bioorg. Med. Chem. 24, 2641–2653 (2016). · DOI
  75. Sánchez-Soto, M. et al. Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist. Mol. Pharm. 89, 457–466 (2016). · DOI
  76. Reyes-Alcaraz, A., Lee, Y. N., Yun, S., Hwang, J. I. & Seong, J. Y. Conformational signatures in beta-arrestin2 reveal natural biased agonism at a G-protein-coupled receptor. Commun. Biol. 1, 128 (2018). · DOI
  77. Yang, Z. & Tao, Y. X. Biased signaling initiated by agouti-related peptide through human melanocortin-3 and -4 receptors. Biochim. Biophys. Acta 1862, 1485–1494 (2016). · DOI
  78. Thompson, G. L. et al. Biased agonism of endogenous opioid peptides at the mu-opioid receptor. Mol. Pharm. 88, 335–346 (2015). · DOI
  79. Dunn, A. D., Reed, B., Erazo, J., Ben-Ezra, A. & Kreek, M. J. Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem. Neurosci. 10, 3590–3600 (2019). · DOI
  80. Peterson, Y. K. & Luttrell, L. M. The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharm. Rev. 69, 256–297 (2017). · DOI · Paper page
  81. Lawlor, N. et al. Single-cell transcriptomes identify human islet cell signatures and reveal cell-type-specific expression changes in type 2 diabetes. Genome Res. 27, 208–222 (2017). · DOI · Paper page
  82. Bucolo, C., Leggio, G. M., Drago, F. & Salomone, S. Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas. Pharm. Ther. 203, 107392 (2019). · DOI · Paper page
  83. Gylfe, E. Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’. Ups. J. Med Sci. 121, 120–132 (2016). · DOI
  84. Wendt, A. & Eliasson, L. Pancreatic α-cells—the unsung heroes in islet function. Semin. Cell Dev. Biol. 103, 41–50 (2020). · DOI
  85. Hauge-Evans, A. C., Bowe, J., Franklin, Z. J., Hassan, Z. & Jones, P. M. Inhibitory effect of somatostatin on insulin secretion is not mediated via the CNS. J. Endocrinol. 225, 19–26 (2015). · DOI
  86. Strowski, M. Z., Parmar, R. M., Blake, A. D. & Schaeffer, J. M. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141, 111–117 (2000). · DOI · Paper page
  87. Keks, N. et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs 34, 473–507 (2020). · DOI
  88. Hope, J., Castle, D. & Keks, N. A. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas. Psychiatry 26, 92–94 (2018). · DOI
  89. Dayabandara, M. et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr. Dis. Treat. 13, 2231–2241 (2017). · DOI · Paper page

Cited by

See all 96

Metadata

Authors
Aslanoglou, D., Bertera, S., Sánchez-Soto, M., Benjamin Free, R., Lee, J., Zong, W., Xue, X., Shrestha, S., Brissova, M., Logan, R. W., Wollheim, C. B., Trucco, M., Yechoor, V. K., Sibley, D. R., Bottino, R., & Freyberg, Z.
Venue
Translational Psychiatry
Published
2021-02-16
Volume
11
Issue
1
ISSN
2158-3188
Cited by
96
References
12
Language
en
Licence
Funders
  • U.S. Department of Defense (PR141292)
  • Pittsburgh Foundation
  • U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
  • U.S. Department of Veterans Affairs (I01BX002678)
  • U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097160)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. https://app.cochat.ai/papers/10.1038/s41398-020-01171-z
The paper
Aslanoglou, D., Bertera, S., Sánchez-Soto, M., Benjamin Free, R., Lee, J., Zong, W., Xue, X., Shrestha, S., Brissova, M., Logan, R. W., Wollheim, C. B., Trucco, M., Yechoor, V. K., Sibley, D. R., Bottino, R., & Freyberg, Z. (2021). Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry. https://doi.org/10.1038/s41398-020-01171-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.